Infrastructure assessment, regulatory track record verification, product specific past experience, QA metrics, time and cost trade-off
Protocol preparation & review, participant & patient recruitment, dosing & sample handling, BA Methodology suitability & validation, PK-PD statistics, report review & submission.
Gap assessment vs FDA/EMA expectations, CAPA planning, audit trails, documentation & governance KPIs to de-risk approvals and keep programs
on schedule.
Leverage our 30+ years of specialized expertise to design regulatory-optimized clinical
programs across dosage formats.
Proven frameworks refined through 2000+ early and late stage PK studies
Access and synergies with leading CROs in India and Europe for in-vivo & in-vitro PK studies
Active collaboration with sponsors and CROs to preempt compliance challenges
We deliver end-to-end bioequivalence (BA/BE) studies and clinical trial solutions for complex formulations, including inhalation products, hybrid 505(b)(2) applications, and therapeutic equivalence assessments.
Dose optimization (e.g., ascending-dose studies for novel delivery systems), Phase III efficacy comparisons.
Tailored submissions for USFDA, EMA, and worldwide agencies, with expertise in psychiatry, diabetology, and oncology
Streamlined pathways for complex generics and innovative therapies, prioritizing patient safety and real-world effectiveness

KAAS BioPharma: Accelerating pharmaceutical innovation through GenAI-powered predictive modeling, strategic clinical development, regulatory excellence, and global partnership for impactful product development.
A 410, Shelton Sapphire, Plot no 18 & 19, Sector 15, CBD Belapur, Navi Mumbai, Maharashtra 400614